Zealand Pharma A/S (ETR:22Z)

Market Cap	2.88B -34.6%
Revenue (ttm)	1.23B +14,598.9%
Net Income	864.30M
EPS	12.08
Shares Out	n/a
PE Ratio	3.34
Forward PE	16.89
Dividend	n/a
Ex-Dividend Date	n/a

Volume	817
Open	42.33
Previous Close	42.02
Day's Range	42.33 - 43.87
52-Week Range	31.45 - 73.90
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	May 7, 2026

About Zealand Pharma

Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark and the United States. The company has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. It also provides Zegalogue, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing insulin and dasiglucagon. Its pipeline includes Dasiglu...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1997
• Employees: 491
• Stock Exchange: Deutsche Börse Xetra
• Ticker Symbol: 22Z

Financial Performance

Financial numbers in DKK